Cargando…

Overexpression of Eag1 potassium channels in clinical tumours

BACKGROUND: Certain types of potassium channels (known as Eag1, KCNH1, Kv10.1) are associated with the production of tumours in patients and in animals. We have now studied the expression pattern of the Eag1 channel in a large range of normal and tumour tissues from different collections utilising m...

Descripción completa

Detalles Bibliográficos
Autores principales: Hemmerlein, Bernhard, Weseloh, Rüdiger M, Mello de Queiroz, Fernanda, Knötgen, Hendrik, Sánchez, Araceli, Rubio, María E, Martin, Sabine, Schliephacke, Tessa, Jenke, Marc, Heinz-Joachim-Radzun, Stühmer, Walter, Pardo, Luis A
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2006
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1621079/
https://www.ncbi.nlm.nih.gov/pubmed/17022810
http://dx.doi.org/10.1186/1476-4598-5-41
_version_ 1782130551482744832
author Hemmerlein, Bernhard
Weseloh, Rüdiger M
Mello de Queiroz, Fernanda
Knötgen, Hendrik
Sánchez, Araceli
Rubio, María E
Martin, Sabine
Schliephacke, Tessa
Jenke, Marc
Heinz-Joachim-Radzun
Stühmer, Walter
Pardo, Luis A
author_facet Hemmerlein, Bernhard
Weseloh, Rüdiger M
Mello de Queiroz, Fernanda
Knötgen, Hendrik
Sánchez, Araceli
Rubio, María E
Martin, Sabine
Schliephacke, Tessa
Jenke, Marc
Heinz-Joachim-Radzun
Stühmer, Walter
Pardo, Luis A
author_sort Hemmerlein, Bernhard
collection PubMed
description BACKGROUND: Certain types of potassium channels (known as Eag1, KCNH1, Kv10.1) are associated with the production of tumours in patients and in animals. We have now studied the expression pattern of the Eag1 channel in a large range of normal and tumour tissues from different collections utilising molecular biological and immunohistochemical techniques. RESULTS: The use of reverse transcription real-time PCR and specifically generated monoclonal anti-Eag1 antibodies showed that expression of the channel is normally limited to specific areas of the brain and to restricted cell populations throughout the body. Tumour samples, however, showed a significant overexpression of the channel with high frequency (up to 80% depending on the tissue source) regardless of the detection method (staining with either one of the antibodies, or detection of Eag1 RNA). CONCLUSION: Inhibition of Eag1 expression in tumour cell lines reduced cell proliferation. Eag1 may therefore represent a promising target for the tailored treatment of human tumours. Furthermore, as normal cells expressing Eag1 are either protected by the blood-brain barrier or represent the terminal stage of normal differentiation, Eag1 based therapies could produce only minor side effects.
format Text
id pubmed-1621079
institution National Center for Biotechnology Information
language English
publishDate 2006
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-16210792006-10-24 Overexpression of Eag1 potassium channels in clinical tumours Hemmerlein, Bernhard Weseloh, Rüdiger M Mello de Queiroz, Fernanda Knötgen, Hendrik Sánchez, Araceli Rubio, María E Martin, Sabine Schliephacke, Tessa Jenke, Marc Heinz-Joachim-Radzun Stühmer, Walter Pardo, Luis A Mol Cancer Research BACKGROUND: Certain types of potassium channels (known as Eag1, KCNH1, Kv10.1) are associated with the production of tumours in patients and in animals. We have now studied the expression pattern of the Eag1 channel in a large range of normal and tumour tissues from different collections utilising molecular biological and immunohistochemical techniques. RESULTS: The use of reverse transcription real-time PCR and specifically generated monoclonal anti-Eag1 antibodies showed that expression of the channel is normally limited to specific areas of the brain and to restricted cell populations throughout the body. Tumour samples, however, showed a significant overexpression of the channel with high frequency (up to 80% depending on the tissue source) regardless of the detection method (staining with either one of the antibodies, or detection of Eag1 RNA). CONCLUSION: Inhibition of Eag1 expression in tumour cell lines reduced cell proliferation. Eag1 may therefore represent a promising target for the tailored treatment of human tumours. Furthermore, as normal cells expressing Eag1 are either protected by the blood-brain barrier or represent the terminal stage of normal differentiation, Eag1 based therapies could produce only minor side effects. BioMed Central 2006-10-05 /pmc/articles/PMC1621079/ /pubmed/17022810 http://dx.doi.org/10.1186/1476-4598-5-41 Text en Copyright © 2006 Hemmerlein et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Hemmerlein, Bernhard
Weseloh, Rüdiger M
Mello de Queiroz, Fernanda
Knötgen, Hendrik
Sánchez, Araceli
Rubio, María E
Martin, Sabine
Schliephacke, Tessa
Jenke, Marc
Heinz-Joachim-Radzun
Stühmer, Walter
Pardo, Luis A
Overexpression of Eag1 potassium channels in clinical tumours
title Overexpression of Eag1 potassium channels in clinical tumours
title_full Overexpression of Eag1 potassium channels in clinical tumours
title_fullStr Overexpression of Eag1 potassium channels in clinical tumours
title_full_unstemmed Overexpression of Eag1 potassium channels in clinical tumours
title_short Overexpression of Eag1 potassium channels in clinical tumours
title_sort overexpression of eag1 potassium channels in clinical tumours
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1621079/
https://www.ncbi.nlm.nih.gov/pubmed/17022810
http://dx.doi.org/10.1186/1476-4598-5-41
work_keys_str_mv AT hemmerleinbernhard overexpressionofeag1potassiumchannelsinclinicaltumours
AT weselohrudigerm overexpressionofeag1potassiumchannelsinclinicaltumours
AT mellodequeirozfernanda overexpressionofeag1potassiumchannelsinclinicaltumours
AT knotgenhendrik overexpressionofeag1potassiumchannelsinclinicaltumours
AT sanchezaraceli overexpressionofeag1potassiumchannelsinclinicaltumours
AT rubiomariae overexpressionofeag1potassiumchannelsinclinicaltumours
AT martinsabine overexpressionofeag1potassiumchannelsinclinicaltumours
AT schliephacketessa overexpressionofeag1potassiumchannelsinclinicaltumours
AT jenkemarc overexpressionofeag1potassiumchannelsinclinicaltumours
AT heinzjoachimradzun overexpressionofeag1potassiumchannelsinclinicaltumours
AT stuhmerwalter overexpressionofeag1potassiumchannelsinclinicaltumours
AT pardoluisa overexpressionofeag1potassiumchannelsinclinicaltumours